Megestrol Acetate for Prevention of Weight Loss During Modern Radiotherapy in Patients With Head and Neck Cancer: A Multicenter Randomized Controlled Trial

BACKGROUND: Weight loss is a common complication during radiotherapy for head and neck cancer and may adversely affect treatment tolerance and outcomes. We evaluated whether megestrol acetate (MA) prevents treatment-related weight loss. METHODS: In this multicenter, open-label randomized controlled trial, 102 patients with non-nasopharyngeal head and neck squamous cell carcinoma undergoing radiotherapy were assigned to MA plus standard care or standard care alone. Standard care consisted of nutritional counseling, symptom management, and feeding-tube placement when clinically indicated. The primary endpoint was change in body weight from baseline to 6 weeks post-radiotherapy. RESULTS: At 6 weeks post-radiotherapy, the MA group showed a mean weight gain of 2.07 kg, whereas the control group lost 1.74 kg (p < 0.01). Weight gain was primarily due to increased fat mass, with no significant difference in muscle mass. Quality of life was similar between groups. CONCLUSION: MA improved weight preservation during radiotherapy and may serve as an adjunct to supportive care in head and neck cancer. TRIAL REGISTRATION: ClinicalTrials.gov identifier: TCTR20240330005.

Authors

Institutions

Publication Details

Journal
Head & Neck
Published
2026-11-18
DOI
https://doi.org/10.1002/hed.70558
Primary Topic
Head and Neck Cancer Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Megestrol Acetate for Prevention of Weight Loss During Modern Radiotherapy in Patients With Head and Neck Cancer: A Multicenter Randomized Controlled Trial

Vatanyu Samakgarn, Pooriwat Muangwong, Imjai Chitapanarux, Piyapasara Toapichattrakul et al.
Head & Neck
Head and Neck Cancer Studies
article

Megestrol Acetate for Prevention of Weight Loss During Modern Radiotherapy in Patients With Head and Neck Cancer: A Multicenter Randomized Controlled Trial

Vatanyu Samakgarn, Pooriwat Muangwong, Imjai Chitapanarux, Piyapasara Toapichattrakul, Panlop Malasri
article en

Abstract

BACKGROUND: Weight loss is a common complication during radiotherapy for head and neck cancer and may adversely affect treatment tolerance and outcomes. We evaluated whether megestrol acetate (MA) prevents treatment-related weight loss. METHODS: In this multicenter, open-label randomized controlled trial, 102 patients with non-nasopharyngeal head and neck squamous cell carcinoma undergoing radiotherapy were assigned to MA plus standard care or standard care alone. Standard care consisted of nutritional counseling, symptom management, and feeding-tube placement when clinically indicated. The primary endpoint was change in body weight from baseline to 6 weeks post-radiotherapy. RESULTS: At 6 weeks post-radiotherapy, the MA group showed a mean weight gain of 2.07 kg, whereas the control group lost 1.74 kg (p < 0.01). Weight gain was primarily due to increased fat mass, with no significant difference in muscle mass. Quality of life was similar between groups. CONCLUSION: MA improved weight preservation during radiotherapy and may serve as an adjunct to supportive care in head and neck cancer. TRIAL REGISTRATION: ClinicalTrials.gov identifier: TCTR20240330005.

Head & Neck
Ministry of Public Health (TH), Lampang Cancer Hospital (TH), Udon Thani Hospital (TH), Chiang Mai University (TH)
Head and Neck Cancer Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon